Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study

What Was Tested

This randomized controlled trial paper looks at HMG (Human Menopausal Gonadotropin) and Triptorelin.

Who Took Part

By PubMed's age tags, the people studied were teenagers and adults, women only.

One hundred seventy-eight women randomized to one of three treatment groups at the start of stimulation.

Midluteally started triptorelin administration was continued until the first day of hMG treatment (group S), or up to and including the fourth day of hMG treatment (group M) or the day of hCG injection (group L).

How the Study Was Run

In design terms this was a randomized, double-blind and multicenter study.

The participants were allocated by chance, so the HMG (Human Menopausal Gonadotropin) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on HMG (Human Menopausal Gonadotropin), so expectations could not easily colour the readings.

Running at several centres spread the HMG (Human Menopausal Gonadotropin) study over different clinics and patient groups.

A double-blind, randomized, multicenter study.

What Was Measured

The subject headings attached to it are Fertility Agents, Female, Fertilization in Vitro, Infertility, Female, Luteinizing Hormone, Luteolytic Agents, Menotropins and Ovarian Follicle.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of HMG (Human Menopausal Gonadotropin) and Triptorelin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (Fertility and sterility), a journal based in United States.

More context: the HMG (Human Menopausal Gonadotropin) compound page and the Triptorelin compound page, all human trials.